Sequential Treatment With Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

Trial Profile

Sequential Treatment With Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 10 Dec 2015 Number of treatment arms changed from 1 to 3, with addition of off therapy as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top